Secondary primary malignancies in indolent non-Hodgkin lymphoma patients receiving frontline bendamustine-rituximab
Davies GA, Prica A, Ante Z, Liu N, Pond GR, Balitsky AK, Suleman A, Mozessohn L. Cancer. 2026; 132(5): e70327.
Letter in reply (no abstract).
Gomes T, Mamdani MM, Dhalla IA, Paterson JM, Juurlink DN. Arch Intern Med. 2011; 171(18):1687-9.
The ICES website uses cookies. If that’s okay with you, keep on browsing, or learn more about our Privacy Policy.